Derivative exercise or conversion — not an open-market buy.
Traded Feb 19, 2026 · Filed Feb 23, 2026
Incyte's President, R&D sold $1.88M of Incyte shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,883,788
Shares × reported transaction price
9 days after results of Feb 10, 2026, 68 days before results of Apr 28, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $101.73 on Feb 19, 2026, 84% above its 52-week low and 8% below its high, after a 5% drop over the previous 30 trading days
52-week range $55.17 (Apr 10, 2025) to $110.57 (Jan 7, 2026), 84% of the way up, from 251 adjusted closes. 30 trading days earlier: $106.66 on Jan 6, 2026. Describes the past only, not a forecast
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -3.0% | -1.0% | -1.9% |
| 30 days | -8.7% | -6.2% | -2.5% |
| 90 days | -3.9% | +9.2% | -13.1% |
| 180 days | +26.6% | +11.1% | +15.6% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$1.76M of Incyte
Automatic sale